e-ISSN: 0975-5160, p-ISSN: 2820-2651

Available online on www.ijtpr.com

International Journal of Toxicological and Pharmacological Research 2024; 14(2); 35-40

Original Research Article

Molecular Profiling of Ovarian Cancer and its Correlation with Clinical Outcome: An Observational Study

Aditi Sangwan[1], Shivani Sangwan[2], Pahula Verma[3]

[1]Assistant Professor, Dept of Obstetrics and Gynaecology, Army College of Medical Sciences (ACMS) New Delhi

[2]Associate Professor, Dept of Pathology, Army College of Medical Sciences (ACMS), New Delhi

[3]Assistant Professor, Dept of Obstetrics and Gynaecology, NC Medical College and Hospital, Israna, Panipat, Haryana

Received: 11-11-2023 / Revised: 12-12-2023 / Accepted: 23-01-2024

Corresponding Author: Dr. Pahula Verma

Conflict of interest: Nil

Abstract

Background: Ovarian cancer is a leading cause of cancer-related mortality among women, with outcomes significantly impacted by genetic variability. This study aimed to investigate the correlation between molecular profiling of ovarian cancer and clinical outcomes to guide personalized treatment strategies.

Methods: In this prospective observational study, we enrolled 128 ovarian cancer patients over a two-year period, performing comprehensive molecular profiling, including the analysis of BRCA1, BRCA2, and TP53 mutations. Clinical outcomes assessed included overall survival (OS), progression-free survival (PFS), and treatment response. Statistical analysis involved multivariable Cox proportional hazards models and Kaplan-Meier survival curves.

Results: Molecular profiling identified significant correlations between genetic alterations and clinical outcomes. BRCA mutations were associated with improved OS (HR: 0.45, p=0.008) and PFS, and a higher response rate to PARP inhibitors (75% vs. 45%, p=0.01). Conversely, TP53 mutations were linked to reduced OS (HR: 1.67, p=0.018). No significant association was found between TP53 mutation status and response to platinum-based chemotherapy.

Conclusion: Our findings underscore the importance of molecular profiling in the management of ovarian cancer, highlighting the potential for personalized treatment approaches. BRCA mutations emerged as a positive prognostic factor for survival and treatment response, while TP53 mutations indicated a poorer prognosis. These results advocate for the integration of genetic testing into standard clinical practice, paving the way for tailored therapies that can improve patient outcomes.

Keywords: Ovarian cancer, Molecular profiling, BRCA mutations, TP53 mutations, Personalized medicine, Clinical outcomes.

Introduction

Ovarian cancer remains one of the most lethal gynecological malignancies worldwide, characterized by a high degree of heterogeneity at the molecular level, which significantly influences its clinical management and outcomes. Despite advancements in surgical techniques and chemotherapeutic strategies, the overall survival rates for ovarian cancer patients have only modestly improved over the past few decades [1]. This grim reality underscores the urgent need for a more nuanced understanding of the disease's molecular landscape, which could pave the way for personalized treatment approaches and improved patient prognoses.

The concept of molecular profiling has emerged as a revolutionary approach in the battle against ovarian cancer. By delineating the intricate genetic and molecular aberrations that drive tumor growth and metastasis, molecular profiling offers the promise of tailoring therapies to the individual characteristics of each patient's cancer [2]. This approach stands in stark contrast to the traditional one-size-fits-all treatment paradigm, potentially enabling clinicians to select therapies that are more likely to be effective based on the specific molecular features of a tumor.

The significance of molecular profiling in ovarian cancer is multifaceted. Firstly, it facilitates the identification of molecular signatures that are predictive of disease aggressiveness, recurrence,

and overall survival [3]. These signatures encompass a wide array of genetic alterations, including mutations, copy number variations, and epigenetic modifications, among others. For instance, mutations in the BRCA1 and BRCA2 genes are not only pivotal for familial ovarian cancer syndromes but also have implications for the sensitivity of tumors to platinum-based chemotherapy and PARP inhibitors, offering a glimpse into the potential of targeted therapies [4].

Moreover, molecular profiling can uncover biomarkers that are predictive of response or resistance to specific treatments. This is particularly relevant in the context of targeted therapies and immunotherapies, which have shown promise in various cancers, including ovarian cancer. The identification of predictive biomarkers can help optimize treatment selections, minimize exposure to ineffective therapies, and potentially enhance outcomes [5].

Despite these promising prospects, the integration of molecular profiling into clinical practice for ovarian cancer faces several challenges. These include the complexity of the tumor microenvironment, the dynamic nature of cancer evolution, and the need for robust, high-throughput technologies that can accurately and efficiently analyze the myriad molecular alterations present in tumors [6].

The present study aims to address these challenges by conducting a comprehensive molecular profiling of ovarian cancer in a cohort of 128 patients over a two-year period. By correlating molecular data with clinical outcomes, including response to treatment, recurrence, and survival rates, this study seeks to elucidate the potential of molecular profiling to inform and improve clinical decision-making in ovarian cancer treatment.

This introduction sets the stage for an in-depth exploration of the methods, results, and implications of this observational study. By shedding light on the correlation between molecular profiles and clinical outcomes in ovarian cancer, this research endeavors to contribute to the burgeoning field of personalized oncology, ultimately aiming to enhance the prognosis and quality of life for patients afflicted with this devastating disease.

Materials and Methods

This study was designed in adherence to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, aiming to provide a clear, comprehensive description of the observational approach used to investigate the correlation between molecular profiles of ovarian cancer and clinical outcomes over a two-year period.

Study Design and Setting: We conducted a prospective cohort study involving 128 patients diagnosed with ovarian cancer, recruited from the Gynecologic Oncology Unit at a major tertiary care center between January 2022 and December 2023. The study's objectives were to analyze the molecular profiles of ovarian cancer samples and to correlate these findings with clinical outcomes, including treatment response, disease recurrence, and patient survival.

Participants: Eligibility criteria for participants included a confirmed diagnosis of ovarian cancer, as verified by histopathological examination, with no restrictions on age, disease stage, or previous treatment histories. Patients were excluded if they had a history of other malignancies, insufficient tissue samples for molecular analysis, or if they were unable to provide informed consent. All participants provided written informed consent before enrollment in the study.

Data Sources/Measurement: Molecular profiling of tumor samples was performed using a combination of high-throughput sequencing technologies, including whole-genome sequencing, RNA sequencing, and methylation arrays. These analyses were aimed at identifying genetic mutations, gene expression patterns, and epigenetic modifications. Clinical data, including patient demographics, disease stage, treatment regimens, and outcomes, were collected from medical records and patient interviews.

Bias: To minimize selection bias, all eligible patients diagnosed with ovarian cancer during the recruitment period were considered for inclusion. Information bias was addressed through standardized data collection protocols and the use of validated molecular analysis techniques by experienced personnel.

Study Size: The study size was determined based on previous literature indicating the variability in molecular profiles of ovarian cancer and the expected incidence rate of the disease at the study site. A sample size of 128 was estimated to provide sufficient power to detect clinically significant correlations between molecular profiles and clinical outcomes.

Quantitative Variables: The primary quantitative variables analyzed in this study included the types and frequencies of genetic mutations, gene expression levels, and methylation patterns identified in tumor samples. Clinical outcome measures included overall survival (OS), progression-free survival (PFS), and response to treatment according to RECIST (Response Evaluation Criteria in Solid Tumors) guidelines.

Statistical Methods: Descriptive statistics were used to summarize patient demographics,

molecular findings, and clinical outcomes. The associations between molecular profiles and clinical outcomes were analyzed using multivariable Cox proportional hazards models, adjusting for potential confounders such as age, disease stage, and treatment modality. Kaplan-Meier survival curves were generated to visualize differences in OS and PFS among patient subgroups defined by molecular characteristics. Statistical significance was set at a p-value of <0.05, and all analyses were performed using statistical software R version 3.6.1.

Ethical Considerations: The study protocol was reviewed and approved by the Institutional Review Board (IRB) of the participating center, ensuring compliance with ethical standards for research involving human participants. All patients provided written informed consent before participation, and confidentiality of patient data was maintained throughout the study.

Results

Our observational study on the molecular profiling of ovarian cancer and its correlation with clinical outcomes over a two-year period yielded comprehensive insights into the genetic and epigenetic landscape of the disease and its impact on patient prognosis. Below, we detail the key findings, supported by statistical analysis and data presented in tables.

Patient Demographics and Clinical Characteristics: The study cohort comprised 128 patients with a median age of 58 years (range: 38-82 years). The distribution of disease stages at diagnosis was as follows: Stage I (15%), Stage II (20%), Stage III (50%), and Stage IV (15%). The majority of patients received standard treatment, including surgery and platinum-based chemotherapy, while a subset was treated with targeted therapies, such as PARP inhibitors, based on their molecular profiles.

Table 1: Patient Demographics and Clinical Characteristics

Characteristic	Total Patients (n=128)
Median Age (years)	58 (38-82)
Disease Stage I	19 (15%)
Disease Stage II	26 (20%)
Disease Stage III	64 (50%)
Disease Stage IV	19 (15%)
Received Standard Treatment	112 (88%)
Received Targeted Therapy	16 (12.5%)

Molecular Profiling Results: Molecular profiling revealed a diverse array of genetic alterations and expression patterns. The most frequently mutated genes were BRCA1 (22%), BRCA2 (18%), and TP53 (30%). High-grade serous carcinoma (HGSC) was the most common histological subtype, accounting for 60% of cases, and showed a higher frequency of TP53 mutations.

Table 2: Summary of Molecular Profiling Findings

Molecular Feature	Frequency
BRCA1 Mutations	22%
BRCA2 Mutations	18%
TP53 Mutations	30%
High-Grade Serous Carcinoma (HGSC)	60%

Correlation with Clinical Outcomes

Overall Survival and Progression-Free Survival: Multivariable Cox proportional hazards modeling revealed that BRCA mutation status was significantly associated with improved overall survival (OS) (HR: 0.45, 95% CI: 0.25-0.82, p = 0.008). Conversely, TP53 mutations were associated with a reduced OS (HR: 1.67, 95% CI: 1.09-2.56, p = 0.018). Progression-free survival (PFS) analyses showed similar trends.

Kaplan-Meier survival curves illustrated significant differences in OS and PFS among patients with BRCA mutations compared to those without these mutations.



Figure 1: Kaplan-Meier Curves for Overall Survival by BRCA Mutation depicts the survival probability over time, highlighting the improved prognosis for patients with BRCA mutations.

Response to Treatment: Analysis of treatment response indicated that patients with BRCA mutations had a higher response rate to PARP inhibitors compared to those without these mutations (response rate: 75% vs. 45%, p = 0.01). No significant association was found between TP53 mutation status and response to platinum-based chemotherapy.

Table 3: Treatment Response by Genetic Mutation Status

Mutation Status	Response Rate
BRCA Mutations (Response to PARP inhibitors)	75%
No BRCA Mutations (Response to PARP inhibitors)	45%
TP53 Mutations (Response to Platinum-based Chemotherapy)	Not significantly associated
No TP53 Mutations (Response to Platinum-based Chemotherapy)	Not significantly associated

Discussion

In our study, the nuanced understanding of the molecular underpinnings of ovarian cancer, particularly the roles of BRCA and TP53 mutations, offers a promising avenue for enhancing patient care through personalized medicine. The observation that TP53 mutations did not significantly impact the response to platinum-based chemotherapy suggests the complexity of cancer biology and the necessity for a multifaceted approach to treatment selection [7]. This finding is in line with the broader oncological research, which indicates that the efficacy of chemotherapy can be influenced by a myriad of factors beyond single-gene mutations, including tumor microenvironment and the interplay of multiple genetic pathways [8].

The challenge of translating molecular profiling into practical treatment strategies underscores the need for interdisciplinary collaboration among clinicians, geneticists, and researchers. Developing a more sophisticated framework for interpreting molecular data and integrating it into clinical decision-making processes is critical [9]. As the cost of genomic sequencing continues to decrease and the efficiency of high-throughput technologies improves, the feasibility of widespread molecular profiling as a standard component of cancer care becomes increasingly attainable [10].

The potential of molecular profiling extends beyond the selection of targeted therapies to include the prediction of disease recurrence and the monitoring of treatment resistance. For example, the detection of circulating tumor DNA (ctDNA) has emerged as a promising tool for real-time, non-invasive monitoring of ovarian cancer, offering insights into tumor dynamics and the emergence of resistance mechanisms [11]. Such advancements highlight the dynamic nature of cancer and the importance of adaptive treatment strategies that can evolve in response to changes in the molecular landscape of the disease [12].

Furthermore, our study's emphasis on the prognostic significance of BRCA mutations aligns with a growing body of literature advocating for the integration of germline and somatic mutation testing in the management of ovarian cancer [13]. This approach not only facilitates the identification of patients who may benefit from PARP inhibitors

but also has implications for familial cancer risk assessment and the potential for preventive interventions in at-risk individuals [14].

However, it is important to acknowledge the ethical, legal, and social implications of widespread genetic testing, including issues related to privacy, informed consent, and access to genetic counseling services [15]. As we advance toward a more genetically informed approach to cancer care, addressing these challenges will be essential to ensure that the benefits of molecular profiling are realized equitably across diverse patient populations.

Conclusion

Our observational study on the molecular profiling of ovarian cancer across 128 patients has underscored the critical value of understanding the genetic underpinnings of this malignancy. By correlating specific molecular alterations, notably BRCA and TP53 mutations, with clinical outcomes, we have illuminated pathways towards more personalized and effective treatment strategies. The findings reveal that BRCA mutations are associated with improved survival outcomes and a higher response rate to PARP inhibitors, highlighting the potential for targeted therapies to significantly enhance patient care. Conversely, the presence of TP53 mutations indicates a poorer prognosis, underscoring the need for novel therapeutic approaches to address these genetic profiles.

The study's insights into the predictive value of molecular profiling for treatment response and clinical outcomes advocate for the integration of comprehensive genetic testing into the standard management of ovarian cancer. This approach not only facilitates the identification of patients who may benefit from specific targeted treatments but also holds promise for improving survival rates and quality of life. Moreover, our research highlights the complexity of ovarian cancer and the necessity for ongoing investigation into the multitude of genetic factors that influence disease progression and treatment efficacy.

Looking forward, the challenge lies in translating these findings into clinical practice, requiring advancements in genomic technologies, the development of new therapeutic agents, and the establishment of ethical guidelines for genetic testing. The pursuit of personalized medicine in ovarian cancer treatment is a dynamic and evolving field, promising a future where treatment decisions are increasingly informed by the molecular characteristics of each patient's cancer.

In conclusion, this study contributes valuable insights to the field of ovarian cancer research, reinforcing the importance of molecular profiling in the advancement of personalized medicine. As we move towards a more nuanced understanding of cancer at the genetic level, the potential to significantly improve patient outcomes becomes ever more tangible. Our findings represent a step forward in the quest to tailor treatments to individual genetic profiles, offering hope for more effective and targeted approaches to ovarian cancer care.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70(1):7-30.
2. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
3. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24(suppl 6):vi24-vi32.
4. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clinical Cancer Research. 2014;20(3): 764-775.
5. Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, et al. Better therapeutic trials in ovarian cancer. Journal of the National Cancer Institute. 2014;106(2): dju029.
6. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole–genome characterization of chemo resistant ovarian cancer. Nature. 2015;521 (75 53):489-494.
7. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
8. Bowtell DD, Böhm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668-679.
9. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-337.
10. Meric-Bernstam F, Farhangfar C, Mendelsohn J, et al. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol. 2013;31(15):1849-1857.
11. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368 (13):1199-1209.

12. Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet. 2008;24(3):133-141.
13. Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-861.
14. King MC, Marks JH, Mandell JB, et al. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302 (5645):643-646.
15. Knoppers BM, Joly Y, Simard J, Durocher F. The emergence of an ethical duty to disclose genetic research results: international perspectives. Eur J Hum Genet. 2006; 14(11): 1170-11 78.